Current Diagnosis and Management of Graves’ Disease

Authors

  • Imam Subekti Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Laurentius Aswin Pramono Department of Internal Medicine, St. Carolus Hospital, Jakarta, Indonesia

Keywords:

Grave's disease, thyroid, American Thyroid Association (ATA), European Thyroid Association (ETA), Japan Thyroid Association/ Japan Endocrine Society

Abstract

Graves’ disease is an autoimmune disorder which affect thyroid gland. Graves’ disease is the most common cause of hyperthyroidism and thyrotoxicosis. Understanding of disease pathophysiology, diagnostic and treatment strategies, and prevention of disease relapse are important for all clinicians especially internal medicine specialist to give optimal and comprehensive management for Graves’ disease patients. This article highlights clinical points to treat Grave’s disease patients from reviews and latest guidelines from American Thyroid Association (ATA), European Thyroid Association (ETA), and Japan Thyroid Association/ Japan Endocrine Society.

References

Weetman AP. Graves' disease. N Eng J Med. 2000;343(17):1236-48.

Barnett PS, McGregor AM. Immunological factors. In Disease of The Thyroid: pathophysiology and management. Wheeler MH dan Lazarus JH (eds). Chapman & Hall Medical. Cambridge UK, 1994; p. 85-103.

Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves’ disease. Trend in Endocrinol Metab. 2005;16(5):243-8.

Subekti I. Diagnosis dan pengelolaan oftalmopati Graves. Dalam Jakarta Endocrinology Meeting. Divisi Metabolik Endokrinologi, Departemen Ilmu Penyakit Dalam FKUI/RSCM Jakarta.2008:30-5.

Drexhage HA. Are there more than antibodies to the thyroid stimulating hormone receptor that meet the eye in Graves’ disease. Endocrinol. 2006;147(1):9-12.

Brent GA. Graves’ Disease. N Engl J Med. 2008;358:2594-605.

Ross DS, Burch HB, Cooper DS, Greenlee C, Laurberg P, Maia AL, Rivkees SA, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 10:1343-421.

Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017; 27(10):1223-31.

Rubio GA, Sengul TK, Vaghaiwalla TM, Parikh PP, Farra JC, Lew JI. Postoperative outcomes in Graves’ disease patients: results from the nationwide inpatient sample database. Presented at the 86th Annual Meeting of the American Thyroid Association, Denver, CO, September 21-25, 2016.

Struja T, Tehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017; 176:87-97.

Eliana F, Soewondo P, Asmarinah, Harahap A, Djauzi S, Prihartono J, et al. The role of cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) gene, Thyroid Stimulating Hormone Receptor (TSHR) gene and regulatory T-cells as risk factors for relapse in patients with Graves’ disease. Acta Med Indones – Indones J Intern Med. 2017;49(3):195-204.

Liu J, Fu J, Xu Y, Wang G. Anti-thyroid drug therapy for Graves’ disease and implications for recurrence. Int J Endocrinol. 2017;1-8.

Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (first edition). Endocrine J. 2016;63(12):1025-64.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016; 5:9-26.

Downloads

Published

2018-06-26

How to Cite

Subekti, I., & Pramono, L. A. (2018). Current Diagnosis and Management of Graves’ Disease. Acta Medica Indonesiana, 50(2), 177. Retrieved from https://actamedindones.org/index.php/ijim/article/view/817

Issue

Vol. 50 No. 2 (2018): Acta Medica Indonesiana

Section

CLINICAL PRACTICE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.